Adalimumab medium‐term dosing strategy in moderate‐to‐severe hidradenitis suppurativa: integrated results from the phase III randomized placebo‐controlled PIONEER trials.
Safety of guselkumab in patients with moderate‐to‐severe psoriasis treated through 100 weeks: a pooled analysis from the randomized VOYAGE 1 and VOYAGE 2 studies.
Efficacy and safety of brodalumab in patients with psoriasis who had inadequate responses to ustekinumab: subgroup analysis of two randomized phase III trials.
713 Do race and ethnicity impact healthcare utilization and costs? A population study among U.S. non-melanoma skin cancer patients
489 Words matter: A randomized controlled study evaluating the impact of decision framing on treatment preferences in adults with psoriasis and psoriatic arthritis
433 The practice of dermatology: Comparison of patient characteristics and healthcare delivery between dermatology and non-dermatology providers
382 Dupilumab treatment provides continued improvements in signs and symptoms through week 100 in patients with moderate-to-severe atopic dermatitis who did not achieve ≥75% reduction in eczema area and severity index at week 16
371 Acne patients on isotretinoin experience less psychological distress and depression symptoms compared to those on oral antibiotics